share_log

Truist Securities Reiterates Buy on Arcus Biosciences, Maintains $50 Price Target

Truist Securities Reiterates Buy on Arcus Biosciences, Maintains $50 Price Target

信托证券重申买入Arcus Biosciences,维持50美元的目标股价
Moomoo 24/7 ·  03/25 11:54

Truist Securities analyst Robyn Karnauskas reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and maintains $50 price target.

Truist Securities分析师罗宾·卡瑙斯卡斯重申Arcus Biosciences(纽约证券交易所代码:RCUS)的买入并维持50美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发